Kerrie Brady, CEO of OcuTerra Therapeutics, shares an update on their eye drop-based integrin inhibitor, which is intended to be a novel therapy for diabetic retinopathy.
Hello, I'm Kerrie Brady and I'm Chief Executive Officer of OcuTerra Therapeutics. We are a Boston-based clinical stage company focusing on a new treatment for diabetic retinopathy.
Our program is developing a selective integrin inhibitor for the use of diabetic retinopathy, but the key is that the molecule has been developed so it can be delivered to the retina via an eye drop. So based on some very promising Phase 1B clinical results in patients with diabetic retinopathy, we've now developed and started to implement our Phase 2 clinical program, the DREAM study—diabetic retinopathy early active management—and looking forward to reporting out the results on that in early 2024.
Note: This transcript has been lightly edited for clarity.